Inactive Instrument

Analyst Reco. HLS Therapeutics Inc Toronto S.E.

Equities

HLS Therapeutics Downgraded to Hold at Stifel GMP on Revenue Concerns; Price Target Cut to C$5.00	Nov. 10	MT
HLS Therapeutics Buy Rating Maintained at Stifel GMP as Growth Expectations Eased; Price Target Cut to C$12.25	23-09-19	MT
HLS Therapeutics Buy Rating Reiterated at Stifel GMP as Vascepa Prescriptions Rise; Price Target Kept at C$26.00	22-12-13	MT
HLS Therapeutics Reiterated at Buy at Stifel GMP on Rising Sales; Price Target Kept at C$32.00	22-09-28	MT
HLS Therapeutics Keeps Buy Rating at Stifel GMP Following Q2 Results; Price Target Cut to C$32.00	22-08-12	MT
HLS Therapeutics Buy Rating Maintained by Stifel GMP as Vascepa Sales Expand	22-07-20	MT

No results for this search